Whereas T cells have been considered the major immune cells of the tumor microenvironment able to induce tumor regression and control cancer clinical outcome, a burst of recent publications pointed to the fact that B cells may also play a prominent role. Activated in germinal centers of tertiary lymphoid structures, B cells can directly present tumor-associated antigens to T cells or produce antibodies that increase antigen presentation to T cells or kill tumor cells, resulting in a beneficial clinical impact. Immune complexes can also increase inflammation, angiogenesis, and immunosuppression via macrophage and complement activation, resulting in deleterious impact.
B cells and cancer: To B or not to B?
Disclosures: T.W.-W. Chen reported personal fees from Novartis, Roche, Eli Lilly, Daiichi Sankyio, and Eisai outside the submitted work. No other disclosures were reported.
F. Petitprez’s present address is MRC Centre for Reproductive Health, The University of Edinburgh, The Queen's Medical Research Institute, Edinburgh, UK.
- Views Icon Views
- Share Icon Share
- Search Site
Wolf Herman Fridman, Florent Petitprez, Maxime Meylan, Tom Wei-Wu Chen, Cheng-Ming Sun, Lubka T. Roumenina, Catherine Sautès-Fridman; B cells and cancer: To B or not to B?. J Exp Med 4 January 2021; 218 (1): e20200851. doi: https://doi.org/10.1084/jem.20200851
Download citation file: